Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 16/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205109 | 0.84 | KDM4E (0.52) | CHRM3LMNAMAPT | |
| SCHEMBL17856295 | 0.84 | CHRM3 (0.73) | CHRM3 | |
| SCHEMBL6664439 | 0.83 | CHRM3 (0.56) | CHRM3ACHE | |
| SCHEMBL4014578 | 0.81 | CHRM3 (0.57) | CHRM3LMNAMAPTBCHEACHE | |
| SCHEMBL17796970 | 0.80 | CHRM3 (0.53) | CHRM3 | |
| SCHEMBL17796971 | 0.80 | CHRM3 (0.53) | CHRM3 | |
| SCHEMBL6419452 | 0.80 | CHRM3 (0.51) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6663459 | 0.78 | CHRM3 (0.58) | CHRM3ACHE | |
| SCHEMBL6421300 | 0.77 | CHRM3 (0.48) | CHRM3BCHEMAOBACHECHRM2 | |
| SCHEMBL21052153 | 0.77 | CHRM3 (0.76) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885LMNA 3315/4885MAPT 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.